Cytek Biosciences, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 127.95M | 164.04M | 193.01M | 200.45M | 201.49M | 0.5% | |
| Cost of Revenue | (48.81M) | (63.06M) | (83.59M) | (89.35M) | (97.03M) | 8.6% | |
Gross Profit | 79.14M | 100.97M | 109.43M | 111.11M | 104.46M | -6.0% | |
| Operating Expenses | |||||||
| Research & Development | (24.44M) | (34.86M) | (44.15M) | (39.40M) | (36.47M) | -7.4% | |
| Selling, General & Administrative | (45.55M) | (67.92M) | (93.12M) | (92.23M) | (108.38M) | 17.5% | |
| General & Administrative | (20.84M) | (34.69M) | (43.97M) | (43.11M) | (58.94M) | 36.7% | |
| Selling & Marketing | (24.71M) | (33.23M) | (49.15M) | (49.11M) | (49.44M) | 0.7% | |
| Depreciation & Amortization | (1.24M) | (5.66M) | (9.23M) | (10.49M) | (11.97M) | 14.2% | |
Operating Income (EBIT) | 9.16M | -1.80M | -27.84M | -20.52M | -40.38M | 96.8% | |
| Non-Operating Items | |||||||
| Interest Income | 49.00K | 4.62M | 6.41M | 10.36M | 2.22M | -78.6% | |
| Interest Expense | (1.74M) | (2.57M) | (2.07M) | — | (474.00K) | — | |
| Other Income/Expenses (Net) | -3.22M | 3.06M | 12.14M | 14.82M | 10.54M | -28.9% | |
Income Before Tax | 5.94M | 1.26M | -15.71M | -5.70M | -29.84M | 423.5% | |
| Income Tax Expense | (2.91M) | (1.22M) | (3.56M) | (320.00K) | (36.70M) | 11368.1% | |
Net Income | 3.00M | 2.58M | -12.15M | -6.02M | -66.54M | 1005.3% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $0 | $0 | $-0 | $-0 | $-1 | 1030.4% | |
| Weighted Avg Shares Outstanding | 133.75M | 134.51M | 135.28M | 130.61M | 127.75M | -2.2% | |
| Weighted Avg Shares Outstanding (Diluted) | 133.75M | 138.56M | 135.28M | 130.61M | 127.75M | -2.2% | |
EBITDA | 8.92M | 9.49M | -4.41M | 4.79M | -17.39M | -463.1% |
Explore CTKB
CTKB in the Healthcare
Small Cap